Skip to main content

ORIGINAL RESEARCH article

Front. Public Health
Sec. Health Economics
Volume 12 - 2024 | doi: 10.3389/fpubh.2024.1413642

Eliciting Medication Preferences of Patients with Type 2 Diabetes under Different Insurance Coverages in China

Provisionally accepted
Lvyun Zheng Lvyun Zheng 1Shimeng Liu Shimeng Liu 2Zhigang Liu Zhigang Liu 1Chenchen Cao Chenchen Cao 1Wenjing Xue Wenjing Xue 1Yingyao Chen Yingyao Chen 2*Jing Liu Jing Liu 1*
  • 1 Hainan Medical University, Haikou, China
  • 2 School of Public Health, Fudan University, Shanghai, Shanghai Municipality, China

The final, formatted version of the article will be published soon.

    Objective: To understand the drug preference of type 2 diabetes mellitus (T2DM) patients with different insurance coverages, and to provide reference for improving the patient-centered clinical treatment decision.Methods:This study used Discrete Choice Experiment (DCE) to measure and discuss preferences of T2DM patients with different insurance coverages in China. A multistage stratified cluster-sampling procedure for data collection and a study of 1409 valid respondent were conducted.Results:Seven attributes have significant influence on the preference of T2DM patients with Urban Employee Basic Medical Insurance,(UEBMI) and Urban and Rural Residents Basic Medical Insurance (URRBMI) (P<0.05).T2DM patients with UEBMI pay the most attention to Gastrointestinal adverse events, while T2DM patients with URRBMI pay the most attention to the Treatment efficacy/reduction in HbA1c. Patients with different medical insurance have different willingness to pay for Cardiovascular benefits, Mode of administration and Weight change. When Gastrointestinal adverse events is changed from higher (40%) to none (0%), patients with UEBMI are willing to pay ¥523.49 more per month, while patients with URRBMI are only willing to pay ¥266.62; When the Treatment efficacy/reduction in HbA1c changes from poor (0.5%) to Highest (2.5%), patients with UEBMI are willing to pay ¥518.44 more per month, while patients with URRBMI are willing to pay ¥328.33 more per month. The Gastrointestinal adverse events and the Treatment efficacy/reduction in HbA1c are the primary factors for T2DM patients with UEBMI and URRBMI, followed by the Hypoglycemic risk.Conclusion:Doctors should consider patients' medication preferences in clinical medication treatment of T2DM patients with different insurance coverages, make targeted treatment decisions, and improve patients' medication compliance to achieve better treatment results.

    Keywords: Insurance Coverage, type 2 diabetes mellitus, medication preference, Discrete choice experiment, China

    Received: 10 Apr 2024; Accepted: 07 Oct 2024.

    Copyright: © 2024 Zheng, Liu, Liu, Cao, Xue, Chen and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Yingyao Chen, School of Public Health, Fudan University, Shanghai, 200032, Shanghai Municipality, China
    Jing Liu, Hainan Medical University, Haikou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.